Please assess the completion status of the following clinical trial:

Trial Title: Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Remission from a major depressive episode after ECT treatment~Exclusion Criteria:~* Suicidality (Hamilton item 3 score of 3 or more)~* Symptoms mania (MAS score of 15 or more)~* Duration of actual depressive episode more than 2 years~* Compulsory measures of any kind~* Dementia~* Severe somatic illness~* Pregnant or lactating subject~* Known clinical relevant malabsorption.~* Epilepsia~* Clinically substantial cognitive deterioration due to ECT treatment~* schizophrenia, schizopreniform or schizo-affective disorder~* Bipolar I, Bipolar II eller~* Rapid cycling bipolar disorder~* Abuse of alcohol or drugs~* Early relapse (less than 2 month) after ECT~* Inadequate contraception~* Known intolerance to any of the used study medications~* Myocardial infarction in the last 6 month~* Clinical important liver disease~* Any known disturbance of the cardiac conduction system, cardiac insufficiency,or other clinical important cardiac disease~* Treatment with a MAO-inhibitor~* Treatment with norepinephrine or epinephrine~* Known hyperthyroidism or treatment with thyroid hormones~* Known ortostatic hypertension.~* Glaucoma~* Known hereditary galactoseintolerance, Lapp Lactase deficiency) or gluco-se/galactosemalabsorption.~* Ongoing treatment with sympatomimetica efedrine, isoprenaline, physostigmine, dopamine, levodopa, phenylephrine.~* Ongoing treatment with anticholinergica, antiparkinson treatment, antihistamines, atropine, biperiden,~* Ongoing treatment with drugs that prolongs the cardiac QT-interval, such as quinidine, antihistamines, terfenadine og sotalole~* Ongoing treatment with fluconazole or terbinafine~* Ongoing treatment with mefloquin.~* Known intolerance to escitalopram~* Ongoing treatment with serotonergic acting substances such as tramadole, sumatriptane

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram 10 mg daily (Type: EXPERIMENTAL): Escitalopram 10 mg daily
- Escitalopram 20 mg daily (Type: EXPERIMENTAL): Escitalopram 20 mg daily
- escitalopram 30 mg daily (Type: EXPERIMENTAL): escitalopram 30 mg daily
- Nortriptylin 100 mg daily (Type: ACTIVE_COMPARATOR): Nortriptylin 100 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).